Lineage Cell Therapeutics, Inc. (LCTX): Cost of Revenue
$334.0K
Year ended 2024-12-31
-38.4%
3-year compound annual growth
-4.1%
5-year compound annual growth
-8.8%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | $334.0K | -50.2% | 2025-03-10, From 2024-01-01 |
| 2023-12-31 | $671.0K | -7.8% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $728.0K | -48.9% | 2024-03-07, From 2022-01-01 |
| 2021-12-31 | $1.43M | +270.4% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $385.0K | -6.6% | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | $412.0K | +36.4% | 2021-03-11, From 2019-01-01 |
| 2018-12-31 | $302.0K | +79.8% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $168.0K | -53.1% | 2019-03-14, From 2017-01-01 |
| 2016-12-31 | $358.0K | -67.7% | 2018-03-15, From 2016-01-01 |
| 2015-12-31 | $1.11M | +32.3% | 2018-03-15, From 2015-01-01 |
| 2014-12-31 | $837.0K | +5.5% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $793.0K | +82.6% | 2016-03-15, From 2013-01-01 |
| 2012-12-31 | $434.3K | +447.0% | 2015-03-11, From 2012-01-01 |
| 2011-12-31 | $79.4K | +186.4% | 2014-03-17, From 2011-01-01 |
| 2010-12-31 | $27.7K | n/a | 2013-03-18, From 2010-01-01 |